{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:01:03Z","timestamp":1791687663497,"version":"4.3.4"},"reference-count":128,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T00:00:00Z","timestamp":1392595200000},"content-version":"vor","delay-in-days":1023,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","oarsijournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoarthritis and Cartilage"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.joca.2010.08.019","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T15:42:08Z","timestamp":1300290128000},"page":"515-542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":295,"title":["Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis"],"prefix":"10.1016","volume":"19","author":[{"given":"V.B.","family":"Kraus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Coindreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cottrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garnero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Henrotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Heineg\u00e5rd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Lohmander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Menetski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Moskowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Persiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-C.","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Todman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joca.2010.08.019_bib1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/sj.clpt.6100017","article-title":"Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs","volume":"81","author":"Wagner","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.joca.2010.08.019_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.joca.2010.08.019_bib3","series-title":"Guidance for Industry: E15 Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories","author":"FDA FaDA","year":"2008"},{"key":"10.1016\/j.joca.2010.08.019_bib4","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.1208\/aapsj0901010","article-title":"Biomarker qualification pilot process at the US Food and Drug Administration","volume":"9","author":"Goodsaid","year":"2007","journal-title":"AAPS J"},{"key":"10.1016\/j.joca.2010.08.019_bib5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.joca.2006.04.001","article-title":"Classification of osteoarthritis biomarkers: a proposed approach","volume":"14","author":"Bauer","year":"2006","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib6","series-title":"Guidance for Industry: Pharmacogenomic Data Submissions","author":"FDA FaDA","year":"2005"},{"key":"10.1016\/j.joca.2010.08.019_bib7","series-title":"E16 Genomic Biomarkers Related to Drug Response: Context, Structure, and Format of Qualification Submissions","author":"FDA FDA","year":"2009"},{"key":"10.1016\/j.joca.2010.08.019_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1359\/jbmr.2003.18.6.1125","article-title":"The Food and Drug Administration\u2019s Osteoporosis Guidance Document: past, present, and future","volume":"18","author":"Colman","year":"2003","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.joca.2010.08.019_bib9","series-title":"Services","article-title":"Guidelines for the clinical evaluation of drugs used in the treatment of osteoporosis","author":"Information OoFo","year":"1979"},{"key":"10.1016\/j.joca.2010.08.019_bib10","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780331101","article-title":"The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand","volume":"33","author":"Altman","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/art.1780340502","article-title":"The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip","volume":"34","author":"Altman","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib13","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1136\/ard.16.4.494","article-title":"Radiological assessment of osteo-arthrosis","volume":"16","author":"Kellgren","year":"1957","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1053\/joca.2002.0853","article-title":"Kellgren & Lawrence grade 1 osteophytes in the knee-doubtful or definite?","volume":"11","author":"Hart","year":"2003","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib15","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/art.24473","article-title":"Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study","volume":"60","author":"Cibere","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.joca.2008.05.004","article-title":"Serum protein signatures detect early radiographic osteoarthritis","volume":"17","author":"Ling","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib17","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/art.22843","article-title":"Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy","volume":"56","author":"Mullan","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib18","first-page":"36","article-title":"Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate","volume":"22","author":"Christgau","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.joca.2007.10.002","article-title":"Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial","volume":"16","author":"Garnero","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib20","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1002\/art.25012","article-title":"Trabecular morphometry by fractal signature analysis is a novel marker of osteoarthritis progression","volume":"60","author":"Kraus","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib21","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/ard.2008.089904","article-title":"One year change of knee cartilage morphology in the first release of participants from the Osteoarthritis Initiative progression subcohort: association with sex, body mass index, symptoms and radiographic osteoarthritis status","volume":"68","author":"Eckstein","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2008.06.001","article-title":"The disease modifying osteoarthritis drug (DMOAD): is it in the horizon?","volume":"58","author":"Qvist","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.joca.2010.08.019_bib23","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1002\/art.20365","article-title":"Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years","volume":"50","author":"Sharif","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib24","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.10576","article-title":"Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis","volume":"46","author":"Garnero","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.joca.2007.01.016","article-title":"The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis","volume":"15","author":"Cahue","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib26","first-page":"799","article-title":"Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III","volume":"24","author":"Bellamy","year":"1997","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","article-title":"OMERACT\u2013OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited","volume":"12","author":"Pham","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.joca.2004.01.006","article-title":"Recommendations for the use of new methods to assess the efficacy of disease-modifying drugs in the treatment of osteoarthritis","volume":"12","author":"Abadie","year":"2004","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib29","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1002\/art.22016","article-title":"Change in joint space width: hyaline articular cartilage loss or alteration in meniscus?","volume":"54","author":"Hunter","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib30","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.joca.2007.12.004","article-title":"Joint space narrowing and Kellgren\u2013Lawrence progression in knee osteoarthritis: an analytic literature synthesis","volume":"16","author":"Emrani","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib31","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.joca.2007.05.012","article-title":"Optimization of the fixed-flexion knee radiograph","volume":"15","author":"Charles","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib32","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.mri.2004.08.001","article-title":"A\u00a0study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees","volume":"22","author":"King","year":"2004","journal-title":"Mag Reson Imaging"},{"key":"10.1016\/j.joca.2010.08.019_bib33","doi-asserted-by":"crossref","DOI":"10.1186\/ar2774","article-title":"Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers","volume":"11","author":"Dam","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2010.08.019_bib34","first-page":"PH65","article-title":"Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study","volume":"14","author":"Lukaszkiewicz","year":"2008","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.joca.2010.08.019_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13547500902777608","article-title":"Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development","volume":"14","author":"Karsdal","year":"2009","journal-title":"Biomarkers"},{"key":"10.1016\/j.joca.2010.08.019_bib36","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M705735200","article-title":"Comp acts as a catalyst in collagen fibrillogenesis","author":"Halasz","year":"2007","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.joca.2010.08.019_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00223-004-0033-0","article-title":"Modulation of collagen fibrillogenesis by dentinal proteoglycans","volume":"76","author":"Milan","year":"2005","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joca.2010.08.019_bib38","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1373\/clinchem.2007.097428","article-title":"N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events from antiinflammatory drugs: a pilot trial","volume":"54","author":"Brune","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.joca.2010.08.019_bib39","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11095-005-2495-9","article-title":"Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report","volume":"22","author":"Lee","year":"2005","journal-title":"Pharm Res"},{"key":"10.1016\/j.joca.2010.08.019_bib40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ab.2006.10.034","article-title":"Discovery and development of a type II collagen neoepitope (TIINE) biomarker for matrix metalloproteinase activity: from in vitro to in vivo","volume":"361","author":"Nemirovskiy","year":"2007","journal-title":"Anal Biochem"},{"key":"10.1016\/j.joca.2010.08.019_bib41","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.joca.2009.02.005","article-title":"The Helix-II epitope: a cautionary tale from a cartilage biomarker based on an invalid collagen sequence","volume":"17","author":"Eyre","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/0003-4819-138-1-200301070-00010","article-title":"Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative","volume":"138","author":"Bossuyt","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joca.2010.08.019_bib43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.joca.2009.02.004","article-title":"Whither osteoarthritis biomarkers?","volume":"17","author":"Felson","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.tox.2007.12.023","article-title":"Strategic paths for biomarker qualification","volume":"245","author":"Goodsaid","year":"2008","journal-title":"Toxicology"},{"key":"10.1016\/j.joca.2010.08.019_bib45","first-page":"607","article-title":"Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema","volume":"34","author":"Lassere","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/art.20740","article-title":"Differential matrix degradation and turnover in early cartilage lesions of human knee and ankle joints","volume":"52","author":"Aurich","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib47","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1002\/art.24856","article-title":"Whole-body bone scintigraphy provides a measure of the total-body burden of osteoarthritis for the purpose of systemic biomarker validation","volume":"60","author":"Addison","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib48","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/art.20493","article-title":"Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study","volume":"50","author":"Garnero","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib49","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.2005.040642","article-title":"Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study","volume":"65","author":"Meulenbelt","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib50","doi-asserted-by":"crossref","first-page":"e9739","DOI":"10.1371\/journal.pone.0009739","article-title":"First qualification study of serum biomarkers as indicators of total body burden of osteoarthritis","volume":"5","author":"Kraus","year":"2010","journal-title":"PLoS ONE"},{"key":"10.1016\/j.joca.2010.08.019_bib51","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1002\/1529-0131(199911)42:11<2356::AID-ANR14>3.0.CO;2-R","article-title":"Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project","volume":"42","author":"Clark","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib52","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/art.10822","article-title":"Ethnic and sex differences in serum levels of cartilage oligomeric matrix protein: the Johnston County Osteoarthritis Project","volume":"48","author":"Jordan","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib53","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/ard.56.8.500","article-title":"Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis","volume":"56","author":"Kobayashi","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"30 Suppl 1","key":"10.1016\/j.joca.2010.08.019_bib54","first-page":"21","article-title":"Molecular markers of processes in cartilage in joint disease","author":"Heinegard","year":"1991","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/ard.60.6.545a","article-title":"Markers of joint destruction: principles, problems, and potential","volume":"60","author":"Young-Min","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib56","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/art.21977","article-title":"Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis","volume":"54","author":"Kong","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib57","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cca.2008.07.031","article-title":"Variation in osteoarthritis biomarkers from activity not food consumption","volume":"398","author":"Gordon","year":"2008","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.joca.2010.08.019_bib58","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.joca.2008.03.006","article-title":"PIIANP and HELIXII diurnal variation","volume":"16","author":"Quintana","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/S1063-4584(07)61740-3","article-title":"Biological variability of biochemical markers of bone, cartilage, and synovial metabolism in patients with knee osteoarthritis: effect of food intake","volume":"15","author":"Garnero","year":"2007","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib60","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s004210050463","article-title":"Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans","volume":"78","author":"Rossler","year":"1998","journal-title":"Eur J Appl Physiol Occup Physiol"},{"key":"10.1016\/j.joca.2010.08.019_bib61","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/clinchem\/46.3.431a","article-title":"Circadian variation in serum CrossLaps concentration is reduced in fasting individuals","volume":"46","author":"Christgau","year":"2000","journal-title":"Clin Chem"},{"key":"10.1016\/j.joca.2010.08.019_bib62","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.joca.2010.01.012","article-title":"Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review applying the consensus BIPED criteria","volume":"18","author":"van Spil","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib63","series-title":"Clinical Trials in Rheumatoid Arthritis and Osteoarthritis","first-page":"249","article-title":"Biochemical markers as surrogate end points of joint disease","author":"Lohmander","year":"2008"},{"key":"10.1016\/j.joca.2010.08.019_bib64","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-007-0017-y","article-title":"Monitoring cartilage turnover","volume":"9","author":"Charni-Ben Tabassi","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.joca.2010.08.019_bib65","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/ncprheum0508","article-title":"Biological markers in osteoarthritis","volume":"3","author":"Rousseau","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib66","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/BOR.0b013e32829fb3b5","article-title":"Type II collagen markers in osteoarthritis: what do they indicate?","volume":"19","author":"Henrotin","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib67","first-page":"61","article-title":"Collagen biomarkers for arthritis applications","volume":"2","author":"Birmingham","year":"2006","journal-title":"Biomarker Insights"},{"key":"10.1016\/j.joca.2010.08.019_bib68","series-title":"Osteoarthritis","first-page":"468","article-title":"Defining and validating the clinical role of molecular markers in osteoarthritis","author":"Lohmander","year":"2003"},{"key":"10.1016\/j.joca.2010.08.019_bib69","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.joca.2006.04.009","article-title":"Association between concentrations of urinary type II collagen neoepitope (uTIINE) and joint space narrowing in patients with knee osteoarthritis","volume":"14","author":"Hellio Le Graverand","year":"2006","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib70","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard.2003.007302","article-title":"Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis","volume":"63","author":"Gineyts","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib71","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S8756-3282(01)00504-X","article-title":"Collagen type II C-telopeptide fragments as an index of cartilage degradation","volume":"29","author":"Christgau","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.joca.2010.08.019_bib72","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/rheumatology\/40.3.315","article-title":"Urinary excretion of glucosyl-galactosyl pyridinoline: a specific biochemical marker of synovium degradation","volume":"40","author":"Gineyts","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.joca.2010.08.019_bib73","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1002\/art.22075","article-title":"Oral salmon calcitonin reduces Lequesne\u2019s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis","volume":"54","author":"Manicourt","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib74","doi-asserted-by":"crossref","first-page":"R625","DOI":"10.1186\/ar1716","article-title":"Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]","volume":"7","author":"Spector","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.joca.2010.08.019_bib75","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/art.22160","volume":"54","author":"Bingham","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/ard.2006.059899","article-title":"Effect of chondroitin sulphate in symptomatic knee osteoarthritis: a multicentre, randomised, double-blind, placebo-controlled study","volume":"66","author":"Mazieres","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib77","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1471-2474-7-98","article-title":"Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis","volume":"7","author":"Andersson","year":"2006","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.joca.2010.08.019_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.joca.2008.02.002","article-title":"Effect of an exercise and dietary intervention on serum biomarkers in overweight and obese adults with osteoarthritis of the knee","author":"Chua","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib79","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/03008208909043899","article-title":"Accumulation of hyaluronate in human lung carcinoma as measured by a new hyaluronate ELISA","volume":"19","author":"Li","year":"1989","journal-title":"Connect Tissue Res"},{"key":"10.1016\/j.joca.2010.08.019_bib80","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/art.1780281209","article-title":"Quantification of keratan sulfate in blood as a marker of cartilage catabolism","volume":"28","author":"Thonar","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib81","first-page":"896","article-title":"Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers","volume":"32","author":"Cibere","year":"2005","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jim.2004.09.005","article-title":"The assessment of cartilage degradation in vivo: development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases","volume":"294","author":"Poole","year":"2004","journal-title":"J\u00a0Immunol Methods"},{"key":"10.1016\/j.joca.2010.08.019_bib83","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1172\/JCI119316","article-title":"Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage","volume":"99","author":"Billinghurst","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.joca.2010.08.019_bib84","first-page":"544","article-title":"Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor","volume":"30","author":"Leff","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib85","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1172\/JCI4853","article-title":"Evidence for altered synthesis of type II collagen in patients with osteoarthritis","volume":"102","author":"Nelson","year":"1998","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.joca.2010.08.019_bib86","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI117156","article-title":"Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay","volume":"93","author":"Hollander","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.joca.2010.08.019_bib87","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1172\/JCI116113","article-title":"Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease","volume":"90","author":"Rizkalla","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.joca.2010.08.019_bib88","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/art.21345","article-title":"Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis","volume":"52","author":"Lohmander","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib89","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.1780350106","article-title":"Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury","volume":"35","author":"Walakovits","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib90","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/ard.2005.041582","article-title":"Urinary levels of type II collagen C-telopeptide crosslink are unrelated to joint space narrowing in patients with knee osteoarthritis","volume":"65","author":"Mazzuca","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.joca.2010.08.019_bib91","first-page":"1147","article-title":"Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis","volume":"33","author":"Mazzuca","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib92","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1002\/art.23025","article-title":"Urinary TIINE concentrations in a randomized controlled trial of doxycycline in knee osteoarthritis: implications of the lack of association between TIINE levels and joint space narrowing","volume":"56","author":"Otterness","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6 Suppl A","key":"10.1016\/j.joca.2010.08.019_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1063-4584(98)80011-3","article-title":"Effects of oral chondroitin sulfate on the progression of knee\u00a0osteoarthritis: a pilot study","author":"Uebelhart","year":"1998","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib94","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0169-6009(91)90143-N","article-title":"Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease","volume":"8","author":"Uebelhart","year":"1990","journal-title":"Bone Miner"},{"key":"10.1016\/j.joca.2010.08.019_bib95","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.joca.2007.09.014","article-title":"Changes in biochemical markers and prediction of effectiveness of intra-articular hyaluronan in patients with knee osteoarthritis","volume":"16","author":"Hasegawa","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib96","first-page":"1721","article-title":"Content and sulfation pattern of keratan sulfate in hip osteoarthritis using high performance liquid chromatography","volume":"27","author":"Yamada","year":"2000","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib97","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0003-2697(89)90061-4","article-title":"Analysis of unsaturated disaccharides from glycosaminoglycuronan by high-performance liquid chromatography","volume":"177","author":"Yoshida","year":"1989","journal-title":"Anal Biochem"},{"key":"10.1016\/j.joca.2010.08.019_bib98","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/art.1780351110","article-title":"Quantitation of chondroitin 4-sulfate and chondroitin 6-sulfate in pathologic joint fluid","volume":"35","author":"Shinmei","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib99","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.phymed.2003.11.001","article-title":"Soy protein may alleviate osteoarthritis symptoms","volume":"11","author":"Arjmandi","year":"2004","journal-title":"Phytomedicine"},{"key":"10.1016\/j.joca.2010.08.019_bib100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/rheumatology\/kel213","article-title":"A\u00a02 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients","volume":"46","author":"Buckland-Wright","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.joca.2010.08.019_bib101","first-page":"430","article-title":"Serum concentrations of type II collagen biomarkers (C2C, C1, 2C and CPII) suggest different pathophysiologies in patients with hip osteoarthritis","volume":"26","author":"Conrozier","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib102","first-page":"850","article-title":"Matrix metalloproteinase-mediated release of immunoreactive telopeptides from cartilage type II collagen","volume":"23","author":"Atley","year":"1998","journal-title":"Trans Orthop Res Soc"},{"key":"10.1016\/j.joca.2010.08.019_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.joca.2008.02.008","article-title":"The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation","author":"Charni-Ben Tabassi","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib104","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.22009","article-title":"Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation","volume":"54","author":"Oestergaard","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib105","first-page":"313","article-title":"Markers of bone type I and cartilage type II collagen degradation in the Hartley guinea pig model of osteoarthritis","volume":"22","author":"Norlund","year":"1997","journal-title":"Trans Orthop Res"},{"key":"10.1016\/j.joca.2010.08.019_bib106","series-title":"The Many Faces of Osteoarthritis","first-page":"275","article-title":"Collagen cross-links as markers of bone and cartilage degradation","author":"Eyre","year":"2002"},{"key":"10.1016\/j.joca.2010.08.019_bib107","article-title":"Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis","author":"Huebner","year":"2009","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib108","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.joca.2007.09.006","article-title":"Biochemical markers of type II collagen breakdown and synthesis are positioned at specific sites in human osteoarthritic knee cartilage","volume":"16","author":"Bay-Jensen","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib109","unstructured":"FDA UFD. 21 CFR Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals 2009; http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=211."},{"key":"10.1016\/j.joca.2010.08.019_bib110","unstructured":"ICH EWG. Validation of analytical procedures: text and methodology Q2(R1), ICH Harmonised Tripartite Guideline. In: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2005."},{"key":"10.1016\/j.joca.2010.08.019_bib111","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2217\/14622416.7.5.773","article-title":"Process map proposal for the validation of genomic biomarkers","volume":"7","author":"Goodsaid","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.joca.2010.08.019_bib112","unstructured":"314.510 C. Approval based upon a surrogate endpoint 2010; http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=314&showFR=1&subpartNode=21:5.0.1.1.4.8"},{"key":"10.1016\/j.joca.2010.08.019_bib113","author":"FDA UFDA","year":"2009"},{"key":"10.1016\/j.joca.2010.08.019_bib114","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.pharmtox.41.1.347","article-title":"Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies","volume":"41","author":"Lesko","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.joca.2010.08.019_bib115","unstructured":"FDA UFDA. Drug-diagnostic co-development concept paper. 2005."},{"key":"10.1016\/j.joca.2010.08.019_bib116","first-page":"1911","article-title":"Reliability of new indices of radiographic osteoarthritis of the hand and hip and lumbar disc degeneration","volume":"20","author":"Lane","year":"1993","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.joca.2010.08.019_bib117","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.joca.2005.06.002","article-title":"Blood-based biomarkers for detecting mild osteoarthritis in the human knee","volume":"13","author":"Marshall","year":"2005","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib118","article-title":"Peripheral blood leukocyte gene expression as biomarkers of disease in knee osteoarthritis (OA)","volume":"56","author":"Krasnokutsky","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib119","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1074\/mcp.R800010-MCP200","article-title":"Banking of biological fluids for studies of disease-associated protein biomarkers","volume":"7","author":"Schrohl","year":"2008","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.joca.2010.08.019_bib120","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ab.2005.04.038","article-title":"Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities","volume":"344","author":"Gerlach","year":"2005","journal-title":"Anal Biochem"},{"key":"10.1016\/j.joca.2010.08.019_bib121","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2353\/jmoldx.2007.060175","article-title":"Isolation of microarray-grade total RNA, microRNA, and DNA from a single PAXgene blood RNA tube","volume":"9","author":"Kruhoffer","year":"2007","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.joca.2010.08.019_bib122","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/pr800401m","article-title":"Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease","volume":"8","author":"Jantos-Siwy","year":"2009","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.joca.2010.08.019_bib123","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/art.10124","article-title":"Urea as a passive transport marker for arthritis biomarker studies","volume":"46","author":"Kraus","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.joca.2010.08.019_bib124","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joca.2008.04.013","article-title":"Novel synovial fluid recovery method allows for quantification of a marker of arthritis in mice","volume":"16","author":"Seifer","year":"2008","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib125","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000232094","article-title":"Early rheumatoid-like lesions in rabbits injected with foreign serum: relationship\u00a0to localization of immune complexes in the lining tissues of joints and cellular content of synovial fluid","volume":"57","author":"Poole","year":"1978","journal-title":"Int Arch Allergy Appl Immunol"},{"key":"10.1016\/j.joca.2010.08.019_bib126","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1128\/aem.57.7.2101-2103.1991","article-title":"Cytotoxicity of T-2 toxin and its\u00a0metabolites determined with the neutral red cell viability assay","volume":"57","author":"Babich","year":"1991","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.joca.2010.08.019_bib127","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1053\/joca.2002.0821","article-title":"A\u00a0comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis","volume":"10","author":"Huebner","year":"2002","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.joca.2010.08.019_bib128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.joca.2006.03.007","article-title":"Assessment of the utility of biomarkers of osteoarthritis in the guinea pig","volume":"14","author":"Huebner","year":"2006","journal-title":"Osteoarthritis Cartilage"}],"container-title":["Osteoarthritis and Cartilage"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458411000732?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1063458411000732?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:24:54Z","timestamp":1761017094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1063458411000732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":128,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1063458411000732"],"URL":"https:\/\/doi.org\/10.1016\/j.joca.2010.08.019","relation":{},"ISSN":["1063-4584"],"issn-type":[{"value":"1063-4584","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis","name":"articletitle","label":"Article Title"},{"value":"Osteoarthritis and Cartilage","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joca.2010.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}